NCX 2111

Drug Profile

NCX 2111

Latest Information Update: 31 Jul 2012

Price : $50

At a glance

  • Originator NicOx
  • Class Antispasmodics; Nitrates; Salicylic acids
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 27 Jul 2012 Discontinued - Preclinical for Overactive bladder in France (unspecified route)
  • 03 Dec 2003 No development reported - Preclinical for Overactive bladder in France (unspecified route)
  • 04 Oct 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top